Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Rest of World
Net revenue	$ 83,612	$ 72,810
U.S.
Rest of World
Net revenue	74,343	65,765
Rest of World
Rest of World
Net revenue	9,269	7,045
Total Drug Products
Rest of World
Net revenue	2,338	1,159
Total Drug Products | U.S.
Rest of World
Net revenue	0	561
Total Drug Products | Rest of World
Rest of World
Net revenue	2,338	598
Total Concentrate Products
Rest of World
Net revenue	81,274	71,651
Total Concentrate Products | U.S.
Rest of World
Net revenue	74,343	65,204
Total Concentrate Products | Rest of World
Rest of World
Net revenue	6,931	6,447
Product Sales - Point-in-time | Drug Product Sales
Rest of World
Net revenue	0	903
Product Sales - Point-in-time | Drug Product Sales | U.S.
Rest of World
Net revenue	0	561
Product Sales - Point-in-time | Drug Product Sales | Rest of World
Rest of World
Net revenue	0	342
Product Sales - Point-in-time | Concentrate Product Sales
Rest of World
Net revenue	79,802	69,162
Product Sales - Point-in-time | Concentrate Product Sales | U.S.
Rest of World
Net revenue	72,871	62,715
Product Sales - Point-in-time | Concentrate Product Sales | Rest of World
Rest of World
Net revenue	6,931	6,447
Product Sales - Point-in-time | Concentrate Product License Fee
Rest of World
Net revenue	1,472	2,489
Product Sales - Point-in-time | Concentrate Product License Fee | U.S.
Rest of World
Net revenue	1,472	2,489
Product Sales - Point-in-time | Concentrate Product License Fee | Rest of World
Rest of World
Net revenue	0	0
License Fee – Over time | Drug License Fee
Rest of World
Net revenue	2,338	256
License Fee – Over time | Drug License Fee | U.S.
Rest of World
Net revenue	0	0
License Fee – Over time | Drug License Fee | Rest of World
Rest of World
Net revenue	$ 2,338	$ 256